

ARCHIVED (NOT ACTIVE – RETIRED)

Archived: 12/15/25

05-82000-33

Original Effective Date: 12/15/03

Reviewed: 12/04/25

Revised: 12/15/25

Next Review: ARCHIVED/NO LONGER IN USE

Subject: Fecal Analysis in the Diagnosis of Intestinal Dysbiosis

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions	Related Guidelines
Other	References	Updates			

DESCRIPTION:

Intestinal dysbiosis may be defined as a state of disordered microbial ecology that is believed to cause disease. Laboratory analysis of fecal samples is proposed as a method of identifying individuals with intestinal dysbiosis and other gastrointestinal disorders. The gastrointestinal tract is colonized by a large number and variety of microorganisms including bacteria, fungi, and archaea. The concept of intestinal dysbiosis rests on the assumption that abnormal patterns of intestinal flora, such as overgrowth of some commonly found microorganisms, have an impact on human health. Symptoms and conditions attributed to intestinal dysbiosis in addition to gastrointestinal disorders include chronic disorders (e.g., irritable bowel syndrome (IBS), inflammatory or autoimmune disorders, food allergy, atopic eczema, unexplained fatigue, arthritis, ankylosing spondylitis), malnutrition, neuropsychiatric symptoms or neurodevelopmental conditions (e.g., autism), breast and colon cancer. Laboratory analysis of both stool and urine has been investigated as markers of dysbiosis. Reference laboratories specializing in the evaluation of dysbiosis may offer comprehensive testing of various aspects of digestion, absorption, microbiology, and metabolic markers.

Summary and Analysis of Evidence: For patients with gastrointestinal conditions such as suspected intestinal dysbiosis, IBS, malabsorption, or small intestinal bacterial overgrowth who receive fecal analysis testing, the evidence includes several cohort and case-control studies comparing fecal

microbiota in patients who had a known disease with healthy controls. The available retrospective cohort studies on fecal analysis have suggested that some components of the fecal microbiome and inflammatory markers may differ across patients with IBS subtypes. No studies were identified on the diagnostic accuracy of fecal analysis versus another diagnostic approach or that compared health outcomes in patients managed with and without fecal analysis tests. No studies were identified that directly informed the use of fecal analysis in the evaluation of intestinal dysbiosis, malabsorption, or small intestinal bacterial overgrowth. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

POSITION STATEMENT:

Fecal analysis of the following components is considered **experimental or investigational** as a diagnostic test for evaluation of intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal overgrowth of bacteria:

- Triglycerides
- Chymotrypsin
- Iso-butyrate, iso-valerate, and n-valerate
- Meat and vegetable fibers
- Long chain fatty acids
- Cholesterol
- Total short chain fatty acids
- Levels of Lactobacilli, bifidobacteria, and Escherichia coli and other “potential pathogens,” including Aeromonas, Bacillus cereus, Campylobacter, Citrobacter, Klebsiella, Proteus, Pseudomonas, Salmonella, Shigella, Staphylococcus aureus, Vibrio
- Identification and quantitation of fecal yeast (including Candida albicans, Candida tropicalis, Rhodotorula, and Geotrichum)
- N-butyrate
- Beta-glucuronidase
- pH
- Short chain fatty acid distribution (adequate amount and proportions of the different short chain fatty acids reflect the basic status of intestinal metabolism)
- Fecal secretory immunoglobulin A (IgA).

The evidence is insufficient to determine the effects of the technology on health outcomes.

BILLING/CODING INFORMATION:

There are no specific CPT or HCPCS codes to report fecal analysis of intestinal dysbiosis.

REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline reviewed date.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#)

DEFINITIONS:

No guideline specific definitions apply.

RELATED GUIDELINES:

[Fecal Microbiota Transplantation, 02-40000-24](#)

OTHER:

Other names used to report fecal analysis of intestinal dysbiosis:

Note: The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

- Comprehensive Digestive Stool Analysis
- Comprehensive Digestive Sool Analysis/Parasitology™
- Complete Digestive Stool Analysis 2.0™
- Fecal Analysis, Intestinal Dysbiosis
- Genova Diagnostics, Comprehensive Digestive Stool Analysis
- Great Smokies Diagnostic Laboratory, Comprehensive Digestive Stool Analysis
- Intestinal Dysbiosis.

REFERENCES:

1. Aasbrenn M, Valeur J, Farup PG. Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity. *Scand J Clin Lab Invest.* 2018 Feb - Apr;78(1-2):109-113. PMID: 29271246.
2. Ansari MH, Ebrahimi M, et al. Viral metagenomic analysis of fecal samples reveals an enteric virome signature in irritable bowel syndrome. *BMC Microbiol.* 2020 May 19;20(1):123.
3. Barclay AR, Morrison DJ, Weaver LT, What is the Role of the Metabolic Activity of the Gut Microbiota in Inflammatory Bowel Disease? Probing for Answers with Stable Isotopes, *J Pediatr Gastroenterol Nutr.* 2008 May; 46(5): 486-95.
4. Blue Cross Blue Shield Association Evidence Positioning System®; 2.04.26- Fecal Analysis in the Diagnosis of Intestinal Dysbiosis, 01/25.
5. Emmanuel A, Landis D, Peucker M, et al. Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome. *Frontline Gastroenterol.* Oct 2016;7(4):275-282.
6. Fumi AL, Trexler K, Rifazimin Treatment for Symptoms of Irritable Bowel Syndrome, *Ann Pharmacother.* 2008 Mar; 42(3): 408-12.

7. GoepfJ, Fowler E, et al. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. *Glob Adv Health Med*. 2014 May;3(3):9-15.
8. Jeffery IB, Das A, et al. Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. *Gastroenterology*. 2020 Mar;158(4):1016-1028.e8. PMID: 31843589.
9. Komanduri S, Gillevet PM, Sikaroodi M, Mutlu E, Keshavarzian A, Dysbiosis in Pouchitis: Evidence of Unique Microfloral Patterns in Pouch Inflammation, *Clin Gastroenterol Hepatol*, 2007 Mar;5(3):352-60.
10. McFarland LV, Dublin S, Meta-Analysis of Probiotics for the Treatment of Irritable Bowel Syndrome, *World J Gastroenterol*. 2008 May 7; 14(17): 2650-61.
11. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M, Efficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials, *Dis Colon Rectum*. 2008 May 9.
12. Packey CD, Sartor RB, Commensal Bacteria, Traditional and Opportunistic Pathogens, Dysbiosis and Bacterial Killing in Inflammatory Bowel Diseases, *Curr Opin Infect Dis*, 2009 June; 22(3): 292-301.
13. Packey CD, Sartor RB, Interplay of Commensal and Pathogenic Bacteria, Genetic Mutations, and Immunoregulatory Defects in the Pathogenesis of Inflammatory Bowel Diseases, *J Intern Med*, 2008 Jun; 263(6): 597-606.
14. Quigley EM, Murray JA, et al. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. *Gastroenterology*. 2020 Oct;159(4):1526-1532. PMID: 32679220.
15. Roediger WE, Nitric Oxide From Dysbiotic Bacterial Respiration of Nitrate in the Pathogenesis and as a Target for Therapy of Ulcerative Colitis, *Aliment Pharmacol Ther*. 2008 Apr 1; 27(7): 531-41.
16. Smalley W, Falck-Ytter C, et al. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). *Gastroenterology*. 2019 Sep;157(3):851-854.
17. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y, Biostructure of Fecal Microbiota in Health Subjects and Patients with chronic Idiopathic Diarrhea, *Gastroenterology*, 2008 Aug; 135(2):568-579.
18. Vatn S, Carstens A, et al. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). *Scand J Gastroenterol*. 2020 Oct;55(10):1146-1156. doi: 10.1080/00365521.2020.1803396. Epub 2020 Aug 11.
19. Whelan K, Judd PA, Tuohy KM, et al. Fecal Microbiota in Patients Receiving Enteral Feeding are Highly Variable and May Be Altered in Those Who Develop Diarrhea, *Am J Clin Nutr* 89: 240-247, 2009.
20. Wilhelm SM, Brubaker CM, Varcak EA, Kale-Pradhan PB, Effectiveness of Probiotics in the Treatment of Irritable Bowel Syndrome, *Pharmacotherapy*, 2008 Apr; 28(4): 496-505.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 12/04/25.

GUIDELINE UPDATE INFORMATION:

12/15/03	New Medical Coverage Guideline.
12/15/04	Reviewed; no change in investigational status.

01/01/06	Annual review; no change in investigational status.
11/15/06	Annual review; no change in investigational status.
07/15/07	Annual review, investigational status maintained, guideline reformatted, references updated.
11/15/08	Annual review: position statement maintained, references updated.
09/15/09	Annual review: position statement maintained, description section and references updated.
05/11/14	Revision: Program Exceptions section updated.
03/15/17	Revision; Investigational position statement maintained; description section and references updated.
03/15/19	Review; Position statement maintained; references updated.
03/15/21	Review; Position statement maintained and references updated.
04/15/22	Review: Position statement maintained; references updated.
01/01/24	Position statements maintained.
03/15/24	Review: Position statement maintained; description and references updated.
12/15/25	Review; Policy archived.